NCT02496663 2026-05-13Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorNational Cancer Institute (NCI)Phase 1 Active not recruiting138 enrolled